Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | ataxin 2 | Starlite/ChEMBL | No references |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Entamoeba histolytica | cell division protein kinase 2, putative | 0.0284 | 0.6246 | 0.5 |
Brugia malayi | Protein kinase domain containing protein | 0.0284 | 0.6246 | 0.6246 |
Brugia malayi | cell division control protein 2 homolog | 0.0284 | 0.6246 | 0.6246 |
Leishmania major | cell division related protein kinase 2,cdc2-related kinase | 0.0284 | 0.6246 | 1 |
Trypanosoma cruzi | cdc2-related kinase 1 | 0.0284 | 0.6246 | 1 |
Trichomonas vaginalis | CMGC family protein kinase | 0.0437 | 1 | 1 |
Loa Loa (eye worm) | CMGC/CDK/CDC2 protein kinase | 0.0284 | 0.6246 | 0.6246 |
Loa Loa (eye worm) | CDC7 protein kinase | 0.0437 | 1 | 1 |
Trypanosoma cruzi | cdc2-related kinase 1 | 0.0284 | 0.6246 | 1 |
Plasmodium falciparum | protein kinase 5 | 0.0284 | 0.6246 | 1 |
Giardia lamblia | Kinase, CDC7 | 0.0437 | 1 | 1 |
Entamoeba histolytica | cell division protein kinase 2, putative | 0.0284 | 0.6246 | 0.5 |
Plasmodium vivax | protein kinase Crk2 | 0.0284 | 0.6246 | 1 |
Toxoplasma gondii | cell-cycle-associated protein kinase CDK, putative | 0.0284 | 0.6246 | 1 |
Trypanosoma brucei | cdc2-related kinase 3 | 0.0284 | 0.6246 | 1 |
Onchocerca volvulus | 0.0437 | 1 | 0.5 | |
Echinococcus granulosus | CDC7 cell division cycle 7 | 0.0437 | 1 | 1 |
Trypanosoma cruzi | cdc2-related kinase 3 | 0.0284 | 0.6246 | 1 |
Echinococcus multilocularis | CDC7 cell division cycle 7 | 0.0437 | 1 | 1 |
Trichomonas vaginalis | CMGC family protein kinase | 0.0437 | 1 | 1 |
Trichomonas vaginalis | CMGC family protein kinase | 0.0437 | 1 | 1 |
Loa Loa (eye worm) | CMGC/CDK/CDK5 protein kinase | 0.0284 | 0.6246 | 0.6246 |
Leishmania major | cell division protein kinase 2,cdc2-related kinase | 0.0284 | 0.6246 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0278 | 0.6086 | 0.6086 |
Onchocerca volvulus | 0.0437 | 1 | 0.5 | |
Loa Loa (eye worm) | CMGC/CDK/CDC2 protein kinase | 0.0284 | 0.6246 | 0.6246 |
Trypanosoma cruzi | cdc2-related kinase 3 | 0.0284 | 0.6246 | 1 |
Schistosoma mansoni | serine/threonine protein kinase | 0.0437 | 1 | 1 |
Trypanosoma brucei | cdc2-related kinase 1 | 0.0284 | 0.6246 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | 0.631 uM | PubChem BioAssay. qHTS for Inhibitors of ATXN expression. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | = 39.8107 um | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of DNA Polymerase Beta. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 44.6684 uM | PubChem BioAssay. qHTS of PTHR Inhibitors: Primary Screen. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 50.1187 uM | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID504404] | ChEMBL. | No reference |
Potency (functional) | = 89.1251 um | PUBCHEM_BIOASSAY: qHTS Assay for the Inhibitors of Schistosoma Mansoni Peroxiredoxins. (Class of assay: confirmatory) [Related pubchem assays: 1011 (Confirmation Concentration-Response Assay for Inhibitors of the Schistosoma mansoni Redox Cascade ), 448 (Schistosoma Mansoni Peroxiredoxins (Prx2) and thioredoxin glutathione reductase (TGR) coupled assay)] | ChEMBL. | No reference |
Potency (functional) | 89.1251 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of Polymerase Iota. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588623] | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.